Health Care & Life Sciences » Pharmaceuticals | Valeant Pharmaceuticals International Inc.

Valeant Pharmaceuticals International Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
5,770
8,206
10,447
9,674
8,724
8,380
Cost of Goods Sold (COGS) incl. D&A
3,154
3,732
4,871
5,284
5,238
4,995
Gross Income
2,616
4,474
5,576
4,390
3,486
3,385
SG&A Expense
1,462
2,272
3,011
3,231
2,943
2,886
EBIT
-
-
2,501
1,159
543
499
Unusual Expense
1,444
670
994
1,713
1,142
2,996
Non Operating Income/Expense
14
487
103
53
686
17
Interest Expense
844
971
1,563
1,836
1,840
1,685
Pretax Income
1,314
1,054
155
2,435
1,741
4,154
Income Tax
451
174
133
27
4,145
10
Consolidated Net Income
864
879
288
2,408
2,404
4,144
Net Income
866
881
292
2,409
2,404
4,148
Net Income After Extraordinaries
866
881
292
2,409
2,404
4,148
Net Income Available to Common
866
881
292
2,409
2,404
4,148
EPS (Basic)
2.70
2.16
0.85
6.94
6.86
11.81
Basic Shares Outstanding
321
335
343
347
350
351
EPS (Diluted)
2.70
2.58
0.85
6.94
6.83
11.81
Diluted Shares Outstanding
321
342
343
347
352
351
EBITDA
2,342
3,885
4,997
4,025
3,401
3,318
Other Operating Expense
174
-
63
-
-
-
Non-Operating Interest Income
8
5
3
8
12
11
Minority Interest Expense
2
1
4
1
-
4

About Valeant Pharmaceuticals International

View Profile
Address
2150 St. Elzéar Boulevard West
Laval Québec H7L 4A8
Canada
Employees -
Website http://www.bauschhealth.com
Updated 07/08/2019
Bausch Health Cos. , Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.